Annual EBITDA
-$143.10 M
-$31.34 M-28.04%
December 31, 2024
Summary
- As of March 4, 2025, TNGX annual EBITDA is -$143.10 million, with the most recent change of -$31.34 million (-28.04%) on December 31, 2024.
- During the last 3 years, TNGX annual EBITDA has fallen by -$85.80 million (-149.76%).
- TNGX annual EBITDA is now -177.95% below its all-time high of -$51.48 million, reached on December 31, 2020.
Performance
TNGX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$40.29 M
-$8.03 M-24.91%
December 31, 2024
Summary
- As of March 4, 2025, TNGX quarterly EBITDA is -$40.29 million, with the most recent change of -$8.03 million (-24.91%) on December 31, 2024.
- Over the past year, TNGX quarterly EBITDA has dropped by -$8.03 million (-24.91%).
- TNGX quarterly EBITDA is now -827.49% below its all-time high of -$4.34 million, reached on June 30, 2021.
Performance
TNGX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$143.10 M
-$5.89 M-4.30%
December 31, 2024
Summary
- As of March 4, 2025, TNGX TTM EBITDA is -$143.10 million, with the most recent change of -$5.89 million (-4.30%) on December 31, 2024.
- Over the past year, TNGX TTM EBITDA has dropped by -$5.89 million (-4.30%).
- TNGX TTM EBITDA is now -434.90% below its all-time high of -$26.75 million, reached on September 30, 2020.
Performance
TNGX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TNGX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.0% | -24.9% | -4.3% |
| 3 y3 years | -149.8% | -24.9% | -4.3% |
| 5 y5 years | -177.9% | -24.9% | -4.3% |
TNGX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -149.8% | at low | -85.4% | +3.2% | -149.8% | at low |
| 5 y | 5-year | -177.9% | at low | -827.5% | +3.2% | -434.9% | at low |
| alltime | all time | -177.9% | at low | -827.5% | +3.2% | -434.9% | at low |
Tango Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$143.10 M(+28.0%) | -$40.29 M(+24.9%) | -$143.10 M(+4.3%) |
| Sep 2024 | - | -$32.26 M(+11.5%) | -$137.20 M(+5.6%) |
| Jun 2024 | - | -$28.92 M(-30.5%) | -$129.96 M(+5.1%) |
| Mar 2024 | - | -$41.63 M(+21.0%) | -$123.68 M(+10.7%) |
| Dec 2023 | -$111.76 M(+2.1%) | -$34.40 M(+37.5%) | -$111.76 M(+4.1%) |
| Sep 2023 | - | -$25.01 M(+10.5%) | -$107.36 M(-4.0%) |
| Jun 2023 | - | -$22.64 M(-23.8%) | -$111.85 M(-2.0%) |
| Mar 2023 | - | -$29.70 M(-1.0%) | -$114.10 M(+4.2%) |
| Dec 2022 | -$109.46 M | -$30.00 M(+1.7%) | -$109.46 M(+8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$29.51 M(+18.5%) | -$101.19 M(+11.2%) |
| Jun 2022 | - | -$24.89 M(-0.7%) | -$91.03 M(+29.1%) |
| Mar 2022 | - | -$25.07 M(+15.4%) | -$70.49 M(+23.0%) |
| Dec 2021 | -$57.29 M(+11.3%) | -$21.73 M(+12.3%) | -$57.29 M(+29.3%) |
| Sep 2021 | - | -$19.34 M(+345.3%) | -$44.31 M(-14.3%) |
| Jun 2021 | - | -$4.34 M(-63.4%) | -$51.72 M(+9.2%) |
| Mar 2021 | - | -$11.88 M(+35.8%) | -$47.38 M(+33.5%) |
| Dec 2020 | -$51.48 M | -$8.75 M(-67.3%) | -$35.50 M(+32.7%) |
| Sep 2020 | - | -$26.75 M | -$26.75 M |
FAQ
- What is Tango Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Tango Therapeutics?
- What is Tango Therapeutics annual EBITDA year-on-year change?
- What is Tango Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Tango Therapeutics?
- What is Tango Therapeutics quarterly EBITDA year-on-year change?
- What is Tango Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Tango Therapeutics?
- What is Tango Therapeutics TTM EBITDA year-on-year change?
What is Tango Therapeutics annual EBITDA?
The current annual EBITDA of TNGX is -$143.10 M
What is the all time high annual EBITDA for Tango Therapeutics?
Tango Therapeutics all-time high annual EBITDA is -$51.48 M
What is Tango Therapeutics annual EBITDA year-on-year change?
Over the past year, TNGX annual EBITDA has changed by -$31.34 M (-28.04%)
What is Tango Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TNGX is -$40.29 M
What is the all time high quarterly EBITDA for Tango Therapeutics?
Tango Therapeutics all-time high quarterly EBITDA is -$4.34 M
What is Tango Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TNGX quarterly EBITDA has changed by -$8.03 M (-24.91%)
What is Tango Therapeutics TTM EBITDA?
The current TTM EBITDA of TNGX is -$143.10 M
What is the all time high TTM EBITDA for Tango Therapeutics?
Tango Therapeutics all-time high TTM EBITDA is -$26.75 M
What is Tango Therapeutics TTM EBITDA year-on-year change?
Over the past year, TNGX TTM EBITDA has changed by -$5.89 M (-4.30%)